OBJECTIVE: Rosiglitazone, a potent agonist of peroxisome proliferator-activated receptor (PPAR)-gamma, exerts anti-inflammatory effects in vitro and in vivo. This study was designated to determine the effects of rosiglitazone on endotoxin-induced acute lung injury in rats. DESIGN: Prospective, experimental study. SETTING: University research laboratory. SUBJECTS: Thirty-six male Wistar rats. INTERVENTIONS: All the animals were randomly assigned to one of six groups (n = 6 per group) and were given either lipopolysaccharide (6 mg/kg intravenously) or saline, pretreated with rosiglitazone (0.3 mg/kg intravenously) or vehicle (10% dimethyl sulphoxide) 30 mins before lipopolysaccharide. The selective PPAR-gamma antagonist GW9662 (0.3 mg/kg intravenously) or its vehicle (10% dimethyl sulphoxide) was given 20 mins before rosiglitazone. MEASUREMENTS AND MAIN RESULTS: Endotoxemia for 4 hrs induced evident lung histologic injury and edema, both of which were significantly attenuated by rosiglitazone pretreatment. The protective effects of rosiglitazone were correlated with the reduction by 71% of the increase of myeloperoxidase activity and the reduction by 84% of the increase of malondialdehyde in the lung tissue. The pulmonary hyperproduction of nitric oxide was reduced by 82% of the increase related to lipopolysaccharide challenge. Pretreatment with rosiglitazone also markedly suppressed lipopolysaccharide-induced expression of inducible nitric oxide synthase messenger RNA and protein in the lung, as demonstrated by reverse transcription-polymerase chain reaction or Western blot analysis. Immunohistochemical analysis revealed that rosiglitazone inhibited the formation of nitrotyrosine, a marker for peroxynitrite reactivity, in the lung tissue. In addition, the specific PPAR-gamma antagonist GW9662 antagonized the effects of rosiglitazone. CONCLUSIONS: This study provides evidence, for the first time, that the PPAR-gamma agonist rosiglitazone significantly reduces endotoxin-induced acute lung injury in rats.
OBJECTIVE:Rosiglitazone, a potent agonist of peroxisome proliferator-activated receptor (PPAR)-gamma, exerts anti-inflammatory effects in vitro and in vivo. This study was designated to determine the effects of rosiglitazone on endotoxin-induced acute lung injury in rats. DESIGN: Prospective, experimental study. SETTING: University research laboratory. SUBJECTS: Thirty-six male Wistar rats. INTERVENTIONS: All the animals were randomly assigned to one of six groups (n = 6 per group) and were given either lipopolysaccharide (6 mg/kg intravenously) or saline, pretreated with rosiglitazone (0.3 mg/kg intravenously) or vehicle (10% dimethyl sulphoxide) 30 mins before lipopolysaccharide. The selective PPAR-gamma antagonist GW9662 (0.3 mg/kg intravenously) or its vehicle (10% dimethyl sulphoxide) was given 20 mins before rosiglitazone. MEASUREMENTS AND MAIN RESULTS: Endotoxemia for 4 hrs induced evident lung histologic injury and edema, both of which were significantly attenuated by rosiglitazone pretreatment. The protective effects of rosiglitazone were correlated with the reduction by 71% of the increase of myeloperoxidase activity and the reduction by 84% of the increase of malondialdehyde in the lung tissue. The pulmonary hyperproduction of nitric oxide was reduced by 82% of the increase related to lipopolysaccharide challenge. Pretreatment with rosiglitazone also markedly suppressed lipopolysaccharide-induced expression of inducible nitric oxide synthase messenger RNA and protein in the lung, as demonstrated by reverse transcription-polymerase chain reaction or Western blot analysis. Immunohistochemical analysis revealed that rosiglitazone inhibited the formation of nitrotyrosine, a marker for peroxynitrite reactivity, in the lung tissue. In addition, the specific PPAR-gamma antagonist GW9662 antagonized the effects of rosiglitazone. CONCLUSIONS: This study provides evidence, for the first time, that the PPAR-gamma agonist rosiglitazone significantly reduces endotoxin-induced acute lung injury in rats.
Authors: Hong Li; Sangya Singh; Raghava Potula; Yuri Persidsky; Georgette D Kanmogne Journal: Am J Respir Crit Care Med Date: 2014-07-01 Impact factor: 21.405
Authors: Carla M T Bauer; Caleb C J Zavitz; Fernando M Botelho; Kristen N Lambert; Earl G Brown; Karen L Mossman; John D Taylor; Martin R Stämpfli Journal: PLoS One Date: 2010-10-12 Impact factor: 3.240
Authors: Alexander Hoetzel; Tamas Dolinay; Simone Vallbracht; Yingze Zhang; Hong Pyo Kim; Emeka Ifedigbo; Sean Alber; A Murat Kaynar; Rene Schmidt; Stefan W Ryter; Augustine M K Choi Journal: Am J Respir Crit Care Med Date: 2008-03-20 Impact factor: 21.405
Authors: Basilia Zingarelli; Paul W Hake; Michael O'Connor; Timothy J Burroughs; Hector R Wong; Joseph S Solomkin; Alex B Lentsch Journal: Crit Care Med Date: 2009-06 Impact factor: 7.598
Authors: Raju C Reddy; Venkata R Narala; Venkateshwar G Keshamouni; Jami E Milam; Michael W Newstead; Theodore J Standiford Journal: Blood Date: 2008-06-05 Impact factor: 22.113